Search

Your search keyword '"Vornicova, Olga"' showing total 29 results
Start Over Author "Vornicova, Olga"
29 results on '"Vornicova, Olga"'

3. Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)

Author

Genta, Sofia, Lajkosz, Katherine, Yee, Noelle R., Spiliopoulou, Pavlina, Heirali, Alya, Hansen, Aaron R., Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Yanekina, Maryia, Sauder, Maxwell B., Keshavarzi, Sareh, Salawu, Abdulazeez, Vornicova, Olga, Butler, Marcus O., Bedard, Philippe L., Razak, Albiruni R. Abdul, Rottapel, Robert, Chruscinski, Andrzej, Coburn, Bryan, and Spreafico, Anna

Published
2023
Full Text
View/download PDF

11. Leiomyosarcoma

Author

Devaud, Nicolas, primary, Vornicova, Olga, additional, Abdul Razak, Albiruni R., additional, Khalili, Korosh, additional, Demicco, Elizabeth G., additional, Mitric, Cristina, additional, Bernardini, Marcus Q., additional, and Gladdy, Rebecca A., additional

Published
2022
Full Text
View/download PDF

12. Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).

Author

Genta, Sofia, primary, Keshavarzi, Sareh, additional, Yee, Noelle, additional, Heirali, Alya, additional, Hansen, Aaron Richard, additional, Siu, Lillian L., additional, Saibil, Samuel, additional, Stayner, Lee-Anne, additional, Yanekina, Maryia, additional, Sauder, Maxwell, additional, Salawu, Abdulazeez, additional, Spiliopoulou, Pavlina, additional, Vornicova, Olga, additional, Vilbert, Maysa Tamara Silveira, additional, Butler, Marcus O., additional, Bedard, Philippe L., additional, Abdul Razak, Albiruni Ryan, additional, Coburn, Bryan, additional, Chruscinski, Andrzej, additional, and Spreafico, Anna, additional

Published
2022
Full Text
View/download PDF

13. Phase 1b study of weekly split-dose selinexor in soft tissue sarcoma (STS).

Author

Salawu, Abdulazeez, primary, Gupta, Abha A., additional, Al-Ezzi, Esmail Mutahar, additional, Genta, Sofia, additional, Malone, Eoghan Ruadh, additional, Vora, Tushar Shailesh, additional, Watson, Geoffrey Alan, additional, Vornicova, Olga, additional, Wang, Lisa, additional, Arones, Limore, additional, Phillips, Madeline J., additional, Lee, Jasmine, additional, and Abdul Razak, Albiruni Ryan, additional

Published
2022
Full Text
View/download PDF

14. Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma.

Author

Genta, Sofia, primary, Araujo, Daniel Vilarim, additional, Keshavarzi, Sareh, additional, Pimentel Muniz, Thiago, additional, Saeed Kamil, Zaid, additional, Howarth, Karen, additional, Terrell, Samantha, additional, Joad, Andy, additional, Ventura, Robert, additional, Covelli, Andrea, additional, Saibil, Samuel, additional, Spiliopoulou, Pavlina, additional, Vornicova, Olga, additional, Easson, Alexandra Maria, additional, Butler, Marcus O., additional, Siu, Lillian L., additional, Bratman, Scott Victor, additional, and Spreafico, Anna, additional

Published
2022
Full Text
View/download PDF

16. The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.

Author

Vornicova, Olga, primary, Wunder, Jay, additional, Chung, Peter W. M., additional, Gupta, Abha A., additional, Gladdy, Rebecca Anne, additional, Catton, Charles N., additional, Salah, Samer, additional, Ferguson, Peter Charles, additional, Tsoi, Kim, additional, Shultz, David Benjamin, additional, Brar, Savtaj Singh, additional, Wong, Philip, additional, Swallow, Carol Jane, additional, Abdul Razak, Albiruni Ryan, additional, and Al-Ezzi, Esmail Mutahar, additional

Published
2021
Full Text
View/download PDF

17. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

Author

Grob, Jean-Jacques, primary, Gonzalez, Rene, additional, Basset-Seguin, Nicole, additional, Vornicova, Olga, additional, Schachter, Jacob, additional, Joshi, Abhishek, additional, Meyer, Nicolas, additional, Grange, Florent, additional, Piulats, Josep M., additional, Bauman, Jessica R., additional, Zhang, Pingye, additional, Gumuscu, Burak, additional, Swaby, Ramona F., additional, and Hughes, Brett G. M., additional

Published
2020
Full Text
View/download PDF

18. A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).

Author

Zer, Alona, primary, Icht, Oded, additional, Joseph, Lilach, additional, Avram, Dana, additional, Jacobi, Oded, additional, Fenig, Eyal, additional, Kurman, Noga, additional, Peretz, Idit, additional, Shamai, Sivan, additional, Merimsky, Ofer, additional, Ben-Ami, Eitan, additional, Shapira, Roni, additional, Schwarzbach, Anna Ewa, additional, Bernstine, Hanna, additional, Weitzen, Rony, additional, Vornicova, Olga, additional, Bar-Sela, Gil, additional, Stemmer, Salomon M., additional, and Lotem, Michal, additional

Published
2020
Full Text
View/download PDF

20. Abstract CT170: KEYNOTE-629: Phase II study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma

Author

Grob, Jean-Jacques, primary, Mendoza, Rene Gonzalez, additional, Basset-Seguin, Nicole, additional, Schachter, Jacob, additional, Vornicova, Olga, additional, Bauman, Jessica, additional, Grange, Florent, additional, Meyer, Nicolas, additional, Piulats, Josep, additional, Zhang, Pingye (Eric), additional, Gumuscu, Burak, additional, Swaby, Ramona, additional, and Hughes, Brett GM, additional

Published
2019
Full Text
View/download PDF

21. KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).

Author

Grob, Jean Jacques, primary, Gonzalez, Rene, additional, Basset-Seguin, Nicole, additional, Schachter, Jacob, additional, Vornicova, Olga, additional, Bauman, Jessica Ruth, additional, Grange, Florent, additional, Meyer, Nicolas, additional, Piulats, Josep M., additional, Zhang, Eric (Pingye), additional, Gumuscu, Burak, additional, Swaby, Ramona F., additional, and Hughes, Brett Gordon Maxwell, additional

Published
2019
Full Text
View/download PDF

29. Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma

Author

Vornicova, Olga, Babichev, Yael, Al-Awar, Rima, Marcellus, Richard, Razak, Albiruni Ryan Abdul, and Rebecca Gladdy

Subjects
Cancer Research, Oncology
Abstract

11560 Background: Leiomyosarcomas (LMS) are genetically heterogeneous tumors that arise from smooth muscle. Currently, the mainstay of systemic treatment for patients with advanced/metastatic disease is doxorubicin (Dox) based CTx. Several genomic analyses of LMS reveal defects in homologous recombination (HR) DNA repair pathway in about half of patients, consistent with a druggable “BRCAness” phenotype. Thus, we sought to determine which combinations of standard CTx and PARPi might be synergistic promising therapeutic strategies for LMS. Methods: Dox, Docetaxel (Doc), Temozolomide (Tmz) were evaluated in combination with PARPi (Olaparib [Ola], Niraparib [Nira] and Talazoparib [Tala]) at 12 different drug concentrations. Four LMS cell lines of different origins (gynecological - GY, abdominal - A, extremity - E) were tested in a high throughput manner. All drug concentrations were chosen according to EC50. Cells were incubated with each combination for 7 days. Viability was assessed by ATPlite Luminescence Assay System.Evaluation of drug combination effect was performed using a Bliss synergy score. This system quantifies the degree of synergy as multiplicative effect of single drugs as if they acted independently. With a synergy score of -5 to 5, the interaction between two drugs is considered as additive; 5 synergistic, and therefore a promising combination. Results: Anticancer activity, ranging from additive to synergistic was seen with all combinations. Results were consistent among all cell lines, independent of site of cell line origin (Table) Most synergistic combination in the majority of LMS cell lines were Dox or Tmz when combined with Tala, reaching up to 15 % and 27% above Bliss respectively. In contrast, Doc showed only additive effect with all analyzed PARPi. Conclusions: The data suggest that the combination of Dox or Tmz with PARPi may represent promising treatment options for LMS patients. Recent clinical studies support this notion in uterine LMS. Importantly these results suggest that such approach may be extended to all sites of LMS. Pre-clinical studies are underway to identify the most promising combinations for future clinical trial design. [Table: see text]

Catalog

Books, media, physical & digital resources
See catalog results